Literature DB >> 34722492

High-Risk Histopathologic Features of Retinoblastoma Treated at a Tertiary Hospital in West Java, Indonesia.

Nur Melani Sari1, Regina Hadiputri2, Maya Sari Kuntorini3, Hasrayati Agustina4, Friska Mardianty5.   

Abstract

PURPOSE: To evaluate the histopathological characteristics of clinically advanced retinoblastoma (RB) and its relationship with tumor differentiation.
METHODS: This was a cross-sectional study of primary enucleated group D/E intraocular RB using medical records from 2017 to 2020 in a tertiary referral hospital. Cases with incomplete histopathological results were excluded. Tumors were classified into well, moderately, and poorly differentiated and undifferentiated. High-risk histopathological features were classified as per Thaung and Karaa [Community Eye Health. 2018;31(101):17-3].
RESULTS: This study included 121 patients (129 eyes), of which 32.2% were diagnosed at 25-36 months. High-risk features (HRFs) were found in 100/129 eyes, and of 73 complete histopathological results, the 2 most common HRFs were postlaminar optic nerve invasion and massive choroidal invasion. RB was poorly differentiated in 69.9% and well differentiated in 12.3% of eyes. There was no statistically significant association between any HRFs and tumor differentiation, with age >2 years associated with tumor differentiation (p < 0.05).
CONCLUSION: The frequency of HRFs is 77.5% of primary enucleated eyes, mainly poorly and undifferentiated cells, particularly in children aged >2 years old.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Age; Developing countries; High-risk pathology features; Retinoblastoma; Tumor differentiation

Year:  2021        PMID: 34722492      PMCID: PMC8531833          DOI: 10.1159/000517100

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  34 in total

1.  Photoreceptor differentiation in retinoblastomas and its significance in prognosis.

Authors:  M Mashiah; Y R Barishak
Journal:  Br J Ophthalmol       Date:  1977-06       Impact factor: 4.638

2.  High Risk Retinoblastoma: Prevalence and Success of Treatment in Developing Countries.

Authors:  H ElZomor; H Taha; A Aleieldin; R Nour; M S Zaghloul; M Fawzi; A Kamel; A S Alfaar
Journal:  Ophthalmic Genet       Date:  2015       Impact factor: 1.803

3.  Clinical predictors of high risk histopathology in retinoblastoma.

Authors:  Seema Kashyap; Rachna Meel; Neelam Pushker; Seema Sen; Sameer Bakhshi; Vishnubhatla Sreenivas; Sumita Sethi; Bhavna Chawla; Supriyo Ghose
Journal:  Pediatr Blood Cancer       Date:  2011-06-30       Impact factor: 3.167

Review 4.  Update on pathology of retinoblastoma.

Authors:  Lata Singh; Seema Kashyap
Journal:  Int J Ophthalmol       Date:  2018-12-18       Impact factor: 1.779

5.  Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma.

Authors:  Swathi Kaliki; Carol L Shields; Sanket U Shah; Ralph C Eagle; Jerry A Shields; Ann Leahey
Journal:  Arch Ophthalmol       Date:  2011-11

6.  High-Risk Histopathology Features in Primary and Secondary Enucleated International Intraocular Retinoblastoma Classification Group D Eyes.

Authors:  Ido D Fabian; Andrew W Stacey; Tanzina Chowdhury; Catriona Duncan; Esin K Karaa; Irene Scheimberg; M Ashwin Reddy; Mandeep S Sagoo
Journal:  Ophthalmology       Date:  2017-03-13       Impact factor: 12.079

7.  High-risk histomorphological features in retinoblastoma and their association with p53 expression: An Indian experience.

Authors:  Rao Seema; Sobti Parul; Khurana Nita
Journal:  Indian J Ophthalmol       Date:  2014-11       Impact factor: 1.848

8.  High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study.

Authors:  Ralph C Eagle
Journal:  Arch Pathol Lab Med       Date:  2009-08       Impact factor: 5.534

Review 9.  Retinoblastoma in Asia.

Authors:  Mukesh Jain; Duangnate Rojanaporn; Bhavna Chawla; Gangadhar Sundar; Lingam Gopal; Vikas Khetan
Journal:  Eye (Lond)       Date:  2018-11-01       Impact factor: 3.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.